Zygolide gives equine vets a new generic pergolide option
Zygolide is entering the equine PPID market as the first FDA-approved generic pergolide tablet for horses, giving veterinarians a new option in one of equine medicine’s most familiar chronic endocrine categories. FDA announced the approval on January 9, 2026, stating that Zygolide is indicated for control of clinical signs associated with pituitary pars intermedia dysfunction, also called equine Cushing’s disease, and that the product is bioequivalent to Prascend. In March, The Horse carried a Dechra promotional carousel that emphasized the product’s peppermint flavor, scored tablet design, and affordability message. (fda.gov)
That matters because pergolide is not a short-course therapy. PPID is a lifelong condition, often diagnosed in older horses and managed over months to years with dose titration, repeat endocrine testing, and close observation of appetite, haircoat, laminitis risk, and overall comfort. Until now, the branded product Prascend has been the main FDA-approved pergolide option in the U.S., after its original approval in 2011. FDA’s freedom of information summary for Zygolide confirms this is the first generic pergolide tablet approved for horses under an abbreviated new animal drug application. (animaldrugsatfda.fda.gov)
The core regulatory story is straightforward. Zygolide contains 1 mg pergolide per tablet, is approved for oral use in horses, and was shown bioequivalent to 1 mg Prascend tablets in a pivotal in vivo blood-level study conducted in 24 healthy horses. The label recommends a starting dose of 2 mcg/kg once daily, with adjustment to effect up to 4 mcg/kg daily. Dechra says the tablets come in 60- and 160-count cartons, and its product materials stress that the tablets are half-scored for dosing to the nearest half-tablet increment. (animaldrugsatfda.fda.gov)
The commercial positioning is also clear. The Horse ad series describes Zygolide as supporting “consistent daily use,” and other industry coverage has framed it as a more cost-effective alternative for horses requiring long-term PPID treatment. Dechra’s product page highlights practical-use features and safety language, including that tablets should not be crushed because of increased human exposure risk. Pregnant or lactating women are advised to wear gloves when administering the drug, and clinicians should be aware that treatment may cause loss of appetite, with weight loss, low energy, and behavioral changes also noted in safety information. (thehorse.com)
Direct expert commentary tied specifically to the U.S. Zygolide launch appears limited in publicly available primary materials so far. Still, the broader industry reaction points to familiar themes: easier administration, lower cost, and better adherence. That focus tracks with earlier equine pergolide product launches, where palatability and dose flexibility were positioned as meaningful differentiators in day-to-day use. Based on Dechra’s marketing and third-party clinic commentary, the company is betting that formulation and price will be the levers that move adoption. That last point is an inference, but it’s a reasonable one given the emphasis across the launch materials. (thehorse.com)
Why it matters: For veterinary professionals, this launch could reshape conversations around compliance more than clinical decision-making. Pergolide’s role in PPID is well established, so the clinical question is not whether the class works, but whether pet parents can sustain treatment and monitoring over time. A generic entrant may reduce cost barriers, especially for larger horses, multi-horse households, or patients needing long-term dose adjustments. If that improves refill persistence, veterinarians may see fewer cases where horses drift out of control because medication was delayed, skipped, or substituted inconsistently. (fda.gov)
There are also workflow implications. A scored tablet and standard FDA-approved labeling may simplify prescribing compared with compounded alternatives, while reinforcing the importance of monitored titration using clinical response and endocrine testing. That could support more standardized care, but it won’t eliminate the need for client education on handling precautions, appetite suppression, and follow-up testing. The historical backdrop matters here: once an approved pergolide product became available, FDA moved away from supporting routine compounded pergolide production, underscoring the agency’s preference for approved products when available. (dechra-us.com)
What to watch: The next signals will be pricing transparency across major equine pharmacies, uptake by ambulatory equine practices, and whether the generic meaningfully changes adherence in real-world PPID management during 2026. It will also be worth watching whether expanded testing access and awareness efforts around PPID lead to earlier diagnosis, which could make lower-cost maintenance therapy even more consequential for equine practice. (thehorse.com)